These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33794441)

  • 1. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
    Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
    Horwitz SM; Scarisbrick JJ; Dummer R; Whittaker S; Duvic M; Kim YH; Quaglino P; Zinzani PL; Bechter O; Eradat H; Pinter-Brown L; Akilov OE; Geskin L; Sanches JA; Ortiz-Romero PL; Weichenthal M; Fisher DC; Walewski J; Trotman J; Taylor K; Dalle S; Stadler R; Lisano J; Bunn V; Little M; Prince HM
    Blood Adv; 2021 Dec; 5(23):5098-5106. PubMed ID: 34507350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
    Prince HM; Kim YH; Horwitz SM; Dummer R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Trotman J; Taylor K; Dalle S; Weichenthal M; Walewski J; Fisher D; Dréno B; Stadler R; Feldman T; Kuzel TM; Wang Y; Palanca-Wessels MC; Zagadailov E; Trepicchio WL; Zhang W; Lin HM; Liu Y; Huebner D; Little M; Whittaker S; Duvic M;
    Lancet; 2017 Aug; 390(10094):555-566. PubMed ID: 28600132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
    Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
    Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study.
    Dummer R; Prince HM; Whittaker S; Horwitz SM; Kim YH; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown L; Sanches JA; Ortiz-Romero PL; Akilov OE; Geskin L; Huen A; Walewski J; Wang Y; Lisano J; Richhariya A; Feliciano J; Zhu Y; Bunn V; Little M; Zagadailov E; Dalal MR; Duvic M
    Eur J Cancer; 2020 Jul; 133():120-130. PubMed ID: 32502876
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Brentuximab Vedotin Versus Physician's Choice of Methotrexate or Bexarotene for the Treatment of Cutaneous T-cell Lymphoma in Canada.
    Elsea D; Savage KJ; Lilley C; Lisano J; Liu J; Yu KS
    Adv Ther; 2023 May; 40(5):2326-2338. PubMed ID: 36920744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Treatment Patterns and Clinical Outcomes With Brentuximab Vedotin or Other Standard Therapies in Patients With Previously Treated Cutaneous T-Cell Lymphoma in the United States.
    Barta SK; Liu N; DerSarkissian M; Chang R; Ye M; Duh MS; Surinach A; Fanale M; Yu KS
    Clin Lymphoma Myeloma Leuk; 2024 Feb; 24(2):e21-e32.e4. PubMed ID: 37919137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
    Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
    J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
    [No Abstract]   [Full Text] [Related]  

  • 9. Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome.
    Lewis DJ; Haun PL; Samimi SS; Vittorio CC; Villasenor-Park J; Barta SK; Landsburg DJ; Svoboda J; Nasta SD; Schuster SJ; Rook AH; Kim EJ
    JAMA Dermatol; 2021 Mar; 157(3):317-321. PubMed ID: 33377934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
    Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
    J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sézary syndrome with variable CD30 positivity.
    Papadavid E; Kapniari E; Pappa V; Nikolaou V; Iliakis T; Dalamaga M; Jonak C; Porkert S; Engelina S; Quaglino P; Ortiz-Romero PL; Vico C; Cozzio A; Dimitriou F; Guiron R; Guenova E; Hodak E; Bagot M; Scarisbrick J
    Br J Dermatol; 2021 Nov; 185(5):1035-1044. PubMed ID: 34137025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A; Hordinsky M; Lazaryan A
    Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RF - Brentuximab as Treatment for CD30
    Morgado-Carrasco D; Combalia A; Estrach Panella T
    Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
    [No Abstract]   [Full Text] [Related]  

  • 14. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
    Scarisbrick JJ
    Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease characteristics, prognosis, and response to therapy in patients with large-cell transformed mycosis fungoides: A single-center retrospective study.
    O'Donnell M; Zaya R; Correia E; Krishnasamy S; Sahu J; Shi W; Cha J; Alpdogan SO; Porcu P; Nikbakht N
    J Am Acad Dermatol; 2022 Jun; 86(6):1285-1292. PubMed ID: 34273458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT.
    Giza A; Miklusiak K; Hałubiec P; Jaworek A; Zimowska-Curyło D; Dyduch G; Sacha T
    Case Rep Dermatol; 2023; 15(1):110-116. PubMed ID: 37497303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin.
    Goyal A; Patel S; Goyal K; Morgan EA; Foreman RK
    J Cutan Pathol; 2019 Nov; 46(11):823-829. PubMed ID: 31286556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case Series on the Use of Brentuximab Vedotin for the Treatment of Mycosis Fungoides.
    Kelly KA; Edenfield L; Seegars MB; Vaidya R; Feldman SR; Strowd LC
    J Drugs Dermatol; 2023 Dec; 22(12):e33-e34. PubMed ID: 38051830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry.
    Muniesa C; Gallardo F; García-Doval I; Estrach MT; Combalia A; Morillo-Andújar M; De la Cruz-Vicente F; Machan S; Moya-Martínez C; Rovira R; Sanchez-Gonzalez B; Acebo E; Amutio E; Peñate Y; Losada-Castillo MDC; García-Muret MP; Iznardo H; Román-Curto C; Cañueto J; Fernández-de-Misa R; Flórez Á; Izu RM; Torres-Navarro I; Zayas A; Pérez-Paredes G; Blanes M; Yanguas JI; Pérez-Ferriols A; Callejas-Charavia M; Ortiz-Romero PL; Pérez-Gil A; Prieto-Torres L; González-Barca E; Servitje O
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):57-64. PubMed ID: 36017748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.